MedPath

Treatment of Tension-type Headache With Articulatory and Suboccipital Soft Tissue Therapy

Not Applicable
Completed
Conditions
Tension-type Headache
Interventions
Other: Manual Therapy
Other: Placebo control
Registration Number
NCT01550276
Lead Sponsor
University of Valencia
Brief Summary

Background. Headache is one of the most common causes of consultation in primary health care and neurology in Europe. Cervical muscle tension can maintain a restriction of joint motion at the suboccipital level, facilitating the referred head pain.

Objective. To evaluate the effectiveness of two manual therapy treatments for tension-type headache.

Methods. A randomized double-blind clinical trial was conducted, for a period of 4 weeks and a follow-up at one month post-treatment. Eighty-four patients with tension-type headache were assigned to 4 groups (3 treatment groups and 1 control group). Treatments included manual therapy of suboccipital soft tissue inhibition, occiput-atlas-axis global manipulation, and a combination of both techniques. Outcome measures were: impact of headache, disability caused by headache, ranges of motion of the craniocervical junction, frequency and intensity of headache, and associated headache symptoms.

Results. After 8 weeks, there were significant improvements in impact of headache (p=0.01), disability (p=0.001), and craniocervical flexion (p=0.03) for the suboccipital soft tissue inhibition group; in headache impact and disability (p=0.000), pain intensity (p=0.02) and craniocervical flexion (p=0.004) and extension (p=0.04) for the occiput-atlas-axis group; and in impact (p=0.002), functional disability (p=0.000), headache frequency (p=0.002) and intensity (p=0.001), craniocervical flexion (p=0.008) and extension (p=0.003) and associated headache symptoms (p=0.01) for the combined therapy group, with effect sizes from medium to large.

Conclusions. Occiput-atlas-axis and combined therapy group treatments are more effective than suboccipital soft tissue inhibition for tension-type headache. The treatment with suboccipital soft tissue inhibition, despite producing less significant results, also has positive effects on different aspects of headache.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
84
Inclusion Criteria
  • Age between 18 and 65 years, episodes of headaches lasting from 30 minutes to 7 days, headache having at least two of the following characteristics: *bilateral location

    • pressing non-pulsating quality
    • mild or moderate intensity
    • not aggravated by routine physical activity.
  • Participants may present photophobia or phonophobia, nausea or vomiting, pericranial tenderness, with evolution of more than three months, and they must be under pharmacological control.

Exclusion Criteria
  • Patients with other types of headache
  • Headache that is aggravated by head movements
  • Metabolic disorders or musculoskeletal complaints previous neck trauma
  • Vertigo
  • Dizziness
  • Arterial hypertension
  • Advanced degenerative osteoarthritis
  • Neck joint stiffness
  • Signs of malignancy
  • Pregnancy
  • Patients with cardiac devices
  • Patients in process of pharmacological adaptation, and excessive emotional tension

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Suboccipital soft tissue inhibitionManual TherapyThe SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
Occiput-atlas-axis global manipulationManual TherapyThe OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
The combination of both treatmentsManual Therapy-
control groupPlacebo control-
Primary Outcome Measures
NameTimeMethod
Firstly, an individual clinical interview was conducted to collect socio-demographic data and characteristics of headache in a one-month base period (the previous 4 weeks)up to 4 weeks

This interview gathers information about age, sex, intensity and frequency of headache (with a Visual Analog Scale from 0 to 10), severity of pain (low, moderate, high), qualities of pain (Bilateral location of pain, Pulsating pressure, Not aggravated by physical activity, Photofobia/Phonofobia, Nausea/Vomiting, Pericranial tenderness), cranial location of pain, family history of headache, triggers, aggravating and pain-relieving factors, as well as any previous physiotherapy treatment for headache relief.

Secondary Outcome Measures
NameTimeMethod
Impact of headache on daily life(HIT-6)up to 8 weeks

It consists of 6 items each with 4 response options ranging from "never" (6 points) to "always" (13 points), and has shown high reliability in previous studies (alpha 0.87).

Headache Disability Inventory (HDI)up to 8 weeks

Two first items concerning the frequency and intensity of headaches and a questionnaire of 25 items assessing emotional and functional aspects with 4 possible response options, with an alpha reliability of 0.76-0.83

Headache pain intensityup to 8 weeks

rated daily by the patient on the 0-10 Visual Analogue Scale (VAS) (0 = no pain, 10 = most severe pain).

Ranges of motion of the craniocervical junctionup to 8 weeks

measured with the CROM-device. This instrument has demonstrated a good intra-tester reliability for the movements of cervical flexion, extension, lateral flexion and rotation (ICC \> 0.80) (ICC\>0.80). However, not having found any previous studies about its reliability for the craniocervical junction (upper cervical joint), we performed -before using this device in our study- an inter-tester reliability analysis with our two examiners and 10 patients not participating in this study, which showed a Pearson's correlation of 0.98

Headache diaryup to 8 weeks

During the four-week treatment period and in the follow-up phase, patients recorded on a daily basis the characteristics of headache with data regarding headache frequency and intensity, associated headache symptoms of photophobia or phonophobia, nausea or vomiting, and pericranial tenderness, completing a total of 7 weekly records.

Trial Locations

Locations (1)

Gemma V Espí López

🇪🇸

Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath